Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism

  title={Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism},
  author={F. Panza and M. Lozupone and Mark I L Watling and B. Imbimbo},
  journal={Expert Opinion on Pharmacotherapy},
  pages={325 - 337}
ABSTRACT Introduction Dementia with Lewy bodies (DLB) has no approved symptomatic or disease-modifying treatments in the US and Europe, despite being the second most common cause of neurodegenerative dementia. Areas covered Herein, the authors briefly review the DLB drug development pipeline, providing a summary of the current pharmacological intervention studies. They then focus on the anticonvulsant zonisamide, a benzisoxazole derivative with a sulfonamide group and look at its value for… Expand


Advances in the pharmacotherapeutic management of dementia with Lewy bodies
An overview of the current pharmacotherapy in DLB is provided and potential new drugs are in ongoing clinical trials and it is likely that novel drug targets for the development of better and more effective symptomatic products and disease-modifying therapies are identified. Expand
Clinical drug development for dementia with Lewy bodies: past and present
An overview of the DLB drug development landscape and the current treatment strategies is provided and new biomarker strategies are necessary to improve diagnostic capabilities and trial designs, and novel drug targets should be identified to develop DLB specific disease-modifying therapies. Expand
Non-pharmacological interventions for Lewy body dementia: a systematic review
Overall, identified studies suggested possible benefits of non-pharmacological interventions in Lewy body dementia, but the small sample sizes and low quality of studies mean no definite recommendations can be offered. Expand
Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.
Daily administration of 25- or 50-mg zonisamide significantly improved motor function compared with placebo; both doses were safe and well tolerated in patients with DLB. Expand
Zonisamide for DLB parkinsonism
An old drug (zonisamide), in a randomized clinical trial, was a safe and effective adjunct to levodopa for the treatment of mild DLB parkinsonism. Expand
Pharmacological Management of Dementia with Lewy Bodies
The three cholinesterase inhibitors that have been shown to be effective in managing the cognitive and behavioral symptoms of DLB: rivastigmine, galantamine and donepezil are discussed. Expand
The role of levodopa in the management of dementia with Lewy bodies
L-dopa was generally well tolerated in DLB but produced a significant motor response in only about one third of patients, and younger DLB cases were more likely to respond to dopaminergic treatment. Expand
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
This study shows that 150 mg and 300’mg doses of Nilotinib appear to be safe and tolerated in subjects with advanced Parkinson’s disease, and suggests that it is warranted to evaluate the safety and efficacy of N Pilotinib in larger randomized, double-blind, placebo-controlled trials. Expand
Diagnosis and Management of Cognitive and Behavioral Changes in Dementia With Lewy Bodies
  • B. Tousi
  • Medicine
  • Current Treatment Options in Neurology
  • 2017
Severe antipsychotic sensitivity, which was a suggestive criterion for DLB diagnosis, is now listed as a supportive feature and REM sleep behavior disorder has been studied more thoroughly in correlation with DLB and is now considered a core feature. Expand
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
Rivastigmine 6-12 mg daily produces statistically and clinically significant behavioural effects in patients with Lewy-body dementia, and seems safe and well tolerated if titrated individually. Expand